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Abstract
Controlling polymorphism in the transition from batch to continuous crystallization represents 
a major obstacle for the pharmaceutical industry. This work demonstrates a novel methodology 
to control the polymorphism of carbamazepine (CBZ) nanoparticles, a highly polymorphic 
BCS class II drug, using a continuous supercritical CO2 antisolvent-assisted nano spray drying 
(SASD) process. We show herein that when supersaturation conditions are achieved in the 
high-pressure SASD nozzle in the presence of anionic additives (e.g. sodium stearate, sodium 
dodecyl sulfate), nanoparticles of the metastable CBZ form II (using sodium stearate) or the 
stable CBZ form III (using sodium dodecyl sulfate) are obtained from methanol solutions, 
respectively. This novel methodology provides control over the final polymorphic form of CBZ 
obtained by (1) templating the desired polymorphic form when supercritical CO2 supersaturates 
the CBZ-additive methanol solution in the nozzle and (2) avoiding/minimizing the occurrence 
of any possible polymorphic transformation by immediately spray drying the supercritical 
antisolvent induced suspension into a dried fine powder. These results contrast with those 
obtained when using non-supersaturating conditions in the SASD nozzle (amorphous CBZ is 
obtained, regardless of the additive used) and when using conventional spray drying (SD) 
where there is no antisolvent effect in the nozzle (CBZ form IV is obtained, regardless of the 
additive used). The impact that the mass ratio of methanol and supercritical CO2 has on the 
supersaturation and consequently on the polymorphic outcome of carbamazepine obtained 
from batch and continuous supercritical CO2 antisolvent crystallization processes is also 
discussed.
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Introduction
Low bioavailability of drug candidates due to poor water solubility accounts for one of the 
greatest obstacles facing the pharmaceutical industry. Poorly soluble compounds represent 
40% of the top 200 oral drugs marketed in the US and 90% of new chemical entities, 
highlighting the importance of establishing a comprehensive method to increase the 
bioavailability of these compounds. 1-2
Carbamazepine (CBZ) is an antiepileptic BCS Class II drug, meaning that it has high intestinal 
permeability but poor water solubility resulting in reduced bioavailability.3 CBZ is a suitable 
Active Pharmaceutical Ingredient (API) model candidate to study polymorphism in 
crystallization processes as it exists in at least four anhydrous polymorphs, with form III being 
the most thermodynamically stable form at room temperature.4-5 Two popular approaches that 
have been successfully used to improve the bioavailability of drugs are (1) generating 
amorphous or metastable forms of the drug and (2) reducing the particle size.6-9 
Polymorphism is a phenomenon that can affect any pharmaceutical drug and is the ability of a 
solid compound to exist in more than one crystalline form. It is estimated that more than 50% 
of active pharmaceutical ingredients have more than one polymorphic form.10-11 Isolating pure 
polymorphic forms has proven to be a challenging task, despite many different techniques 
employed to achieve this.12-14 Impurities, in the form of various other polymorphic forms, is 
one of the most common obstacles that the pharmaceutical industry faces during the 
manufacture of an API.15-17Although continuous crystallization boasts higher levels of control 
over some process variables when compared to batch processes, robust approaches to control 
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polymorphism during continuous crystallization has yet to be comprehensively achieved. Only 
recently have researchers attempted to address the complexity of controlling polymorphism in 
continuous crystallization processes.18-20 As a result of this, the pharmaceutical industry have 
placed their focus on polymorphic studies to avoid adverse effects such as spontaneous 
conversion between different crystalline phases and to take advantage of beneficial effects such 
as improved physicochemical properties and patent life extensions.15, 21-22 Polymorphism can 
result in differences in physicochemical properties leading to differences in solubility, 
dissolution rate and bioavailability which are critical parameters for the pharmaceutical 
industry.23-24 Polymorphism can be affected by various processing conditions in 
pharmaceutical crystallization such as the type of crystallization mode used (batch versus 
continuous), solvent, temperature, antisolvent, and the use of additives or surfactants.18, 25-30 
The use of additives to control polymorphism has been explored by many researchers in an 
attempt to isolate pure forms of both stable and metastable polymorphs of various compounds. 
26, 31-35 Davey et al. have studied the effect of additives on generating and isolating metastable 
polymorphs for various compounds.32-33 In many cases when additives are selected for this 
purpose, they have been shown to incorporate themselves stereoselectively into the growing 
faces of the crystals, thereby inhibiting further growth of these faces and promoting alternative 
polymorphic forms. 32-33, 36-37 Another technique that may also be utilized to control the 
polymorphism of different compounds includes the confinement of crystallization habitats.38-
39 It has been reported that the size constraint imposed by nano- and submicron- scale pores 
during crystallization can influence the final polymorphic form obtained. 39-41 The confinement 
can cause the relative free-energy values for various polymorphs to become almost equivalent, 
thereby reducing the preference for one polymorphic form to crystallize over another.40-42
This paper reports on the transition of a supercritical antisolvent crystallization process from 
batch to continuous, a development trend that is encouraged by most regulatory bodies for 
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pharmaceutical manufacturing processes.43-44  Currently, pharmaceutical companies are 
reluctant to make the switch as designing a continuous manufacturing process typically 
requires a higher level of process control and monitorization than batch manufacturing 
processes in addition to further investment in plant.44-46 Scaling up represents itself as one of 
the major obstacles that limits pharmaceutical processing due to difficulties arising from the 
prediction of lab-scale to industrial-scale evolutions.45 One of the selling points for continuous 
manufacturing is that the requirement for scaling up is removed as emphasis is shifted to scaling 
down instead. Evidence shows that making the switch could prove worthwhile in the long term 
as continuous manufacturing provides: 47-48
 Fewer steps in the process, resulting in faster production times.
 Lower costs.
 Real time in-line monitoring of experimental runs using quality-by-design approaches. 
 Possibility of scaling-down instead of scaling-up.
Continuous processing features heavily in most fields of research as it is expected that these 
techniques will dominate the first choice crystallization mode for the pharmaceutical industry. 
Pharmaceutical techniques such as plug flow crystallization, milling, high-pressure 
homogenization and antisolvent methods have recently become a popular and effective 
technique to control particle size, shape and polymorphic form of APIs.49-53 Supercritical fluid 
(SCF) technologies have also emerged as techniques which can be employed in batch, semi-
continuous and more recently in continuous mode (in spray drying methods which use CO2 as 
the atomizing fluid), to generate unique polymorphic forms of APIs which are not reproducible 
by other techniques.54 Supercritical fluid methods provide benefits over conventional 
precipitation methods in regards to generating high levels of supersaturation, polymorphic 
control, particle size control, low residual, as well as providing low levels of residual solvent 
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in the final product.55-59 Carbon dioxide is the most commonly used SCF as it is non-toxic, 
inexpensive and has the ability to act as an antisolvent.26, 59 Another reason for the popularity 
of carbon dioxide as a supercritical fluid is due to its low critical temperature and relatively 
low critical pressure (Tc = 31.1°C , Pc = 7.38 MPa).59-60 This low temperature allows 
manufacturers to process thermally sensitive pharmaceutical compounds using this SCF. 
Supercritical CO2 has a low viscosity and a high diffusivity coefficient making it a viable 
candidate for antisolvent processing. 59, 61 An additional benefit of using supercritical CO2 as 
an antisolvent is that there is less risk of a hydrate forming during processing as would be a 
concern when using water, a common antisolvent in pharmaceutical crystallization. 62
Although supercritical fluid techniques can utilize supercritical CO2 in three different roles (as 
a solvent, antisolvent or atomization enhancer), this work presented herein utilizes supercritical 
CO2 as both an antisolvent and atomization enhancer. In our supercritical CO2 antisolvent-
assisted nano spray drying method (SASD) presented herein, supercritical CO2 mixes with the 
solution containing the drug and additives in a small volume high pressure co-axial nozzle. 
Supersaturation is induced in the nozzle and nucleation follows. Unlike other processes such 
as the gas antisolvent (GAS) crystallization process, atomization is involved in the SASD 
method which results in the generation of a spray of ultra-fine droplets in which the solvent is 
removed by thermal means. This process is an attractive method for the pharmaceutical 
industry as it can be easily adapted to existing conventional spray dryers. As the region of high 
pressure is concentrated to the small volume mixing chamber (nozzle), there is little 
requirement for specialist high-pressure equipment. 
Padrela et al. demonstrated that the use of additives provides control over the molecular 
packing of carbamazepine (CBZ) molecules at the pre-nucleation stage in a batch supercritical 
antisolvent process, resulting in the production of specific polymorphic forms of CBZ.26 These 
authors used density functional theory modeling to predict that nonpolar parts of CBZ 
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molecules interact with the nonpolar tails of the anionic additive, sodium stearate (SS), 
resulting in the templating of empty columnar channels which SS can interact with for the 
generation of CBZ form II. The absence of these channels is observed when sodium dodecyl 
sulfate is selected, which causes templating of CBZ to represent form III.26 The objective of 
the work presented herein is to investigate if this effect can be replicated in a continuous SASD 
process, as the kinetics and mechanisms for crystallization in each of these processes (batch 
versus continuous) are expected to be different. Supercritical CO2 nano spray drying and 
related supercritical antisolvent methods typically promote the formation of metastable 
crystalline forms of APIs due to their fast crystallization and drying steps.57, 63 However, our 
novel methodology presented herein uses molecular additives in an SASD process to enable 
control over the final API polymorphic form generated (exemplified herein for carbamazepine 
as our model system). This approach consists of continuously templating the desired 
polymorphic form of CBZ in the nozzle (where supercritical CO2 antisolvent mixes with the 
solution containing the drug and the additive) by using specific additives before crystallization 
takes place (which will mostly occur after the nozzle exit during the spray drying step). 
In this work a supercritical antisolvent method, which was demonstrated elsewhere for the 
production of distinct polymorphic forms of CBZ microparticles,26 is converted into a 
continuous SASD method for the production of distinct polymorphic forms of CBZ 
nanoparticles. A Design of Experiments (DoE) methodology was applied to study the influence 
of selected process parameters (e.g. solution feed rate, % of additive) on the polymorphic 
outcome of CBZ produced by the supercritical CO2 antisolvent nano spray drying method 
(SASD). The mass ratio of supercritical CO2 and methanol required to achieve supersaturation 
and consequently precipitation of CBZ was determined using a batch supercritical antisolvent 
method, and this information was used to select the required processing conditions in SASD to 
ensure that supersaturation is achieved. This paper also aims to clarify if the influence of 
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additives on the polymorphism of CBZ is only caused by the antisolvent effect of CO2 in the 




Carbamazepine (form III) was purchased from Kemprotec. Maltitol, sodium stearate (SS), 
ethyl cellulose, sodium dodecyl sulfate (SDS), sodium deoxycholate and pluronic F-127 were 
purchased from Sigma Aldrich and used without further purification (purity was >99.9%). 
Eudragit L-100-55 was a gift from Evonik Industries. Carbon dioxide (99.98%) was supplied 
by BOC (Ireland). Table 1 summarizes the different types of additives used in this work. These 
additives were selected from a manuscript previously reported by Padrela et al. where they 
were shown to favor the formation of either pure forms II or III of carbamazepine in a batch 
supercritical antisolvent method. 26
Table 1. Type of Additives Used in the Preparation of Carbamazepine Solutions in 
Methanol for Supercritical-CO2 Antisolvent-Assisted Nano Spray Drying
Anionic Surfactants Non-ionic surfactants Anionic polymers Non-ionic polymers
Sodium stearate Maltitol Eudragit L-100-55 Ethyl cellulose
Sodium dodecyl 






For the precipitation experiments of carbamazepine (CBZ) using a batch supercritical 
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antisolvent process, 50 mg of Carbamazepine (CBZ) was dissolved in 1 ml of methanol and 
placed in an ultrasonic bath until the solids were completely dissolved (~5 minutes). For the 
production of carbamazepine nanoparticles using a supercritical CO2 antisolvent-assisted nano 
spray drying (SASD) process, CBZ with/without additives was dissolved in 20 ml of methanol 
(50.0 mg/ml) and placed in an ultrasonic bath for a similar period of time as mentioned above. 
When using additives for the preparation of CBZ solutions in methanol, 5% w/w (2.5 mg/ml) 
of each additive was dissolved in the CBZ solutions. When low concentration experimental 
runs (SASD 20, 21 and 22) were completed, the concentration of CBZ was reduced to 17.0 
mg/ml and 5% w/w of specific additives (0.8 mg/ml) were added. The solutions were then 
filtered through a 0.2µm pore size nylon filter (Whatman Inc., Florham Park, NJ) to remove 
any undissolved material. 
Precipitation of Carbamazepine in a batch supercritical antisolvent process
In order to determine the pressures and the mass ratios of solution to supercritical CO2 at which 
supersaturation would occur in the SASD nozzle, precipitation of CBZ was performed using a 
batch supercritical antisolvent process. This apparatus consisted of a 10 cm3 stainless steel 
high-pressure vessel shown in Fig. 1 and as described elsewhere.26 The pressure was 
determined using a pressure transducer (Omega model PX603). A high-pressure stainless steel 
storage vessel was used to store the CO2 to allow it to reach the set temperature inside a 
temperature-controlled (monitored by a T-type thermocouple) air chamber. A solution 
containing 50 mg of CBZ dissolved in 1 ml of methanol was placed inside the high-pressure 
vessel and compressed with CO2 at a rate of 1 MPa/minute. During the addition of CO2, the 
solution was subjected to magnet stirring at 600 rpm to facilitate homogeneity. Once 
precipitation was visually observed through the borosilicate window, the value was recorded 
(Table 6) and the vessel was depressurized. This value was determined to be the antisolvent 
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crystallization point. Although this methodology does not consider that the batch and 
continuous processes are kinetically different, it provides an indication on the pressure and 
mass ratio of supercritical CO2 to methanol at which supersaturation should occur in the SASD 
high-pressure nozzle. Each solubility experiment was performed at least three times to ensure 
repeatability.
Figure 1.  Schematic diagram of the batch supercritical antisolvent apparatus used for 
solubility testing. 1, CO2 cylinder; 2, gas compressor; 3, temperature controlled air chamber; 
4, stainless steel storage cylinder; 5, magnetic stirrer plate; 6, high-pressure vessel; 7, exit 
valve; PIC: pressure controller; TC: temperature controller.
Supercritical CO2 Antisolvent-Assisted Nano Spray Drying (SASD)
Figure 2 shows a schematic of the SASD apparatus. The primary spray drying apparatus 
consists of three main zones that are representative of the supercritical antisolvent nano spray 
drying process (SASD). The first zone is the high-pressure small-volume stainless steel nozzle 
(number 5 in Fig. 2), where both mixing of CO2 with the CBZ solution, and 
supersaturation/antisolvent nucleation occur. The mixing volume for this section is 0.1 cm3. 
The second zone is the drying chamber which is a 1000 cm3 vessel (number 6 in Fig. 2) 
surrounded by a temperature controlled water jacket which facilitates the drying of the solvent 
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once atomized. The final zone is the particle collector, which consists of a metal filter (number 
7 in Fig. 2) and filter nylon paper with 0.2 µm pore size.
During an SASD experiment, CO2 was compressed using a Teledyne ISCO 260D pump. The 
pressure and temperature were controlled as described above. The nozzle was maintained at 
50°C by using heating resistors in close proximity to the nozzle. The CBZ methanol solution 
was pumped by a Waters 515 HPLC pump to the high-pressure SASD nozzle where it mixed 
with the supercritical CO2. After the solution was passed through the nozzle, the CO2 was 
depressurized and any residual solvent was evaporated during the spray drying step. The 
samples were harvested and stored in a desiccator prior to characterization to prevent exposure 
to humidity which could result in polymorphic conversions over time.
Three control SASD experiments were performed at different solution flow rates (0.10, 0.25 
and 0.40 ml/min) to identify the polymorphic form of CBZ obtained by the SASD method in 
the absence of additives (Table 2). The pressure selected for these experiments was 12.0 MPa 
(which corresponded to a solution to SCF ratio of 0.005-0.021) as it was determined to be 
sufficient for antisolvent crystallization (a solution to SCF mass ratio of 0.5 was determined to 
be the maximum value allowable  using a batch supercritical antisolvent method) to occur. 
Upon completion of these experiments , several additives (selected from the work reported by 
Padrela et al.26) were added to the CBZ methanol solutions and processed using the SASD 
method, as reported in Table 3. The pressure selected for these experiments was 17.0 MPa 
(solution to SCF ratio of 0.011) which was sufficiently over the pressure required for 
antisolvent crystallization to occur.
Table 2. List of Carbamazepine (CBZ) Solid Forms Obtained at Different Solution Flow 
Rates Without the Use of Additives Using Supercritical CO2 Antisolvent-Assisted Nano 
Spray Drying (SASD) a
Sample 
Reference
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SASD 1 0.10 0.079 0.005 I/III
SASD 2 0.25 0.198 0.013 I/III
SASD 3 0.40 0.316 0.021 I/III
aFor all SASD experiments listed in Table 2, pressure was kept at 12.0 MPa and CO2 flow rate 
was kept at approximately 15.0 g/min (30 ml/min). Temperature was 50°C. The concentration 
of active ingredient (CBZ) was 50 mg/ml in methanol. FSolution: solution flow rate; RFlow Ratio: 
mass flow-rate ratio of the solution to (CO2).
Figure 2. Schematic diagram of the continuous SASD apparatus. 1, CO2 cylinder; 2, gas 
compressor; 3, CBZ solution flask connected to a HPLC pump; 4, temperature-controlled CO2 
storage cylinder; 5, high-pressure nozzle; 6, drying chamber; 7, filter; 8, Temperature 
controlled air chamber; TC: temperature controller; PIC: pressure controller;.
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Table 3. List of Carbamazepine (CBZ) Solid Forms Obtained Using Supercritical CO2 
Antisolvent-Assisted Nano Spray Drying (SASD) b
Sample 
Reference Additive








SASD 4 No additive 50.0 17.0 0.011 I/III
SASD 5 Maltitol 50.0 17.0 0.011 I
SASD 6 Sodium stearate (SS) 50.0 17.0 0.011 II
SASD 7 Ethyl cellulose 50.0 17.0 0.011 Amorphous
SASD 8 Sodium dodecyl sulfate (SDS) 50.0
17.0 0.011 I/III
SASD 9 L-Eudragit 100-55 50.0 17.0 0.011 I
SASD 10 Pluronic F-127 50.0 17.0 0.011 I and III
SASD 11 Sodium deoxycholate 50.0 17.0 0.011 I and III
SASD 20 No additive 17.0 12.0 0.013 Amorphous
SASD 21 Sodium stearate 17.0 12.0 0.013 Amorphous
SASD 22 Sodium dodecyl sulfate 17.0 12.0 0.013 Amorphous
bFor all SASD additive screening experiments, temperature was 50 °C and solution flow rate 
was 0.20 g/min (0.25 ml/min). When additives were used, the concentration of each additive 
in the CBZ solutions was 5% w/w. P: pressure inside the high-pressure nozzle; C[CBZ]: 
concentration of carbamazepine (CBZ) in methanol.
Design of Experiments (DoE)
When changing the type of additives, as listed in Table 3, 5% w/w of certain additives was 
determined to be a sufficient amount to produce pure polymorphs of CBZ. Two additives, 
sodium dodecyl sulfate (SDS) and sodium stearate (SS) were selected for a Design of 
Experiments (DoE) approach, as shown in Fig. 3. This DoE investigated the influence of the 
solution flow rate and % (w/w) additive on the polymorphism of CBZ obtained by the SASD 
process, as reported in Table 4. The pressure used for both of these DoE approaches was 12.0 
MPa. This was as a result of higher pressures (17.0 MPa) from the screening runs in Table 3 
resulted in blockages of the nozzle due to significant precipitation taking place prior to passing 
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through the small volume (0.01 cm3) nozzle.
Figure 3. Design of Experiment (DoE) schematic to investigate the effect of additive quantity 
and solution flow rate on the polymorphic forms of CBZ obtained by the SASD process.
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Table 4. Experimental Conditions Used in SASD Runs for a Design of Experiments (DoE) 







%Additive                                     
(w/w)
FSolution   
(ml/min)







1 SASD 12 SDS 1 0.10 0.079 0.005 I and III
2 SASD 13 SDS 10 0.10 0.079 0.005 I and III
3 SASD 14 SDS 10 0.40 0.316 0.021 I and III
4 SASD 15 SDS 1 0.40 0.316 0.021 III
5 SASD 8 SDS 5 0.25 0.198 0.013 I and III
6 SASD 16 SS 1 0.10 0.079 0.005 I and II
7 SASD 17 SS 10 0.10 0.079 0.005 I and II
8 SASD 18 SS 10 0.40 0.316 0.021 I and II
9 SASD 19 SS 1 0.40 0.316 0.021 I and II
10 SASD 6 SS 5 0.25 0.198 0.013 II
cFor all DoE runs, concentration of CBZ in methanol was 50 mg/ml, temperature was 50°C, 
pressure was maintained at 12.0 MPa and CO2 flow rate was kept at approximately 15.0 g/min 
(30 ml/min). %Additive: proportion of additive used in each experimental run; FSolution: solution 
flow rate; RFlow Ratio: mass flow-rate ratio of the solution to SCF (CO2).
Conventional spray drying
All samples (SD 1 to 6) were spray dried by a Büchi B-290 mini spray dryer. The inert loop 
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was enabled in conjunction with a condenser at −20 °C to facilitate the use of organic solvents. 
The CBZ solid particles were collected by a high efficiency cyclone. A 2-fluid nozzle with 0.7 
mm cap was employed for atomizing the methanol solutions containing CBZ with/without 
additives. Nitrogen was selected as the atomizing gas with flow rate of ∼473 NL/h (P = 0.10 
mPa and T = 0°C) and the aspirator was set to 100 % (35.0 m3/h). The final spray dried powders 
were collected and transferred to a desiccator after production until further characterization. A 
list of all the experiments performed using the Büchi B-290 mini spray dryer are reported in 
Table 5.
Table 5. Experimental Conditions used in Conventional Spray Drying (SD) Runs and List 










SD 1 No additive - 50.0 IV
SD 2 SS 5 50.0 IV
SD 3 SDS 5 50.0 IV
SD 4 No additive - 17.0 IV
SD 5 SS 5 17.0 IV
SD 6 SDS 5 17.0 IV
d For all runs, outlet temperature was 50 °C. %Additive: quantity of additive used; C[CBZ]:  
concentration of carbamazepine (CBZ) in methanol.
Solid-state characterization
Powder X-Ray Diffraction (PXRD) in reflection mode was preformed using an Empyrean 
diffractometer (PANalytical, Phillips) with Cu Kα radiation (λ = 1.5406 Å) at room 
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temperature. Samples were lightly pressed on a zero-background disc and placed on a sample 
holder. Each spectrum was recorded at a tube voltage of 40 kV and a tube current of 40 mA, 
with a step size of 0.02 ° (2θ) and a scan speed of 0.102° (2θ·s-1) in the angular range of 5° to 
30° (2θ) with 4 rpm. 
Scanning electron microscopy (SEM) analysis was performed on a Hitachi SU-70 system 
operating at 10 kV. Samples were mounted onto aluminum stubs with double-sided carbon 
tape. The stubs were placed inside a gold sputter coater (Emitech K550X) and coated with a 
plasma current of 20 mA for two minutes.
Results and Discussion
Precipitation of carbamazepine in a batch supercritical antisolvent process
The precipitation of carbamazepine (CBZ) by supercritical antisolvent crystallization was 
experimentally observed in a batch high-pressure vessel, prior to performing supercritical CO2 
antisolvent-assisted nano spray drying (SASD) experiments. These batch precipitation 
experiments contributed to our understanding of the pressures and the solution to CO2 
antisolvent mass ratios necessary to induce supersaturation and consequently antisolvent 
nucleation of CBZ in the mixing chamber of the SASD nozzle. A range of ±5 °C of the 
operating temperature in the batch supercritical antisolvent process was selected to account for 
any possible temperature drop (caused by heat loss in the nozzle due to the Joule-Thomson 
effect) or increase (caused by an overcompensation of the heating resistors in the nozzle). Table 
6 shows that at solution to CO2 ratios between 0.49-0.55, precipitation of CBZ occurred due to 
antisolvent crystallization inside the batch vessel using the selected temperature ranges. 
Table 6. Experimental Conditions Required for the Precipitation of Carbamazepine in a 
Batch Supercritical Antisolvent Process e 
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t (°C) P (MPa)
RMass Ratio
Solution/SCF
45 8.72 ± 0.04 0.55
50 9.66 ± 0.01 0.50
55 10.17 ± 0.10 0.49
eFor all precipitation tests, concentration of CBZ in methanol was 50 mg/ml, stirring rate was 
600 rpm and pressure was increased at a rate of 1 MPa/min until reaching the final pressure. P: 
pressure in the batch pressure vessel; t: temperature in the air chamber; RMass Ratio: mass ratio of 
solution to supercritical fluid (CO2).
Production of CBZ nanoparticles by the supercritical CO2 antisolvent-assisted nano spray 
drying (SASD) method with/without additives
In order to ensure that the primary crystallization mechanism in the SASD method would be 
initiated by antisolvent supersaturation/nucleation in the nozzle, a working pressure of 17.0 
MPa was selected for all screening experiments (mass flow ratio of solution to supercritical 
fluid is 0.013 which is suitable to induce supersaturation). Despite a short residence time of the 
fluids (CO2 and drug solution) in the SASD nozzle, some blockages occurred at this high 
pressure. As a result, the pressure was reduced to 12.0 MPa (mass flow ratio of solution to 
supercritical fluid is between 0.005-0.021) which is still sufficient to induce supersaturation by 
the CO2 antisolvent effect, and helps minimizing any blockages in the SASD nozzle due to 
crystal growth of CBZ. 
The aim of this work is to investigate whether CBZ polymorphism can be controlled in a 
continuous supercritical crystallization process, as previously demonstrated in a batch 
supercritical crystallization process26. Padrela et al. showed that form II and form III of CBZ 
could be obtained using a batch supercritical process when using the anionic additives, sodium 
stearate and sodium dodecyl sulfate, respectively. 26 Prior to investigating whether additives 
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could control the polymorphic form of CBZ during the supercritical CO2 antisolvent-assisted 
nano spray drying (SASD) process, three control experiments were completed at each of the 
different solutions rates used in this study without the use of additives. It must be noted that 
the nano/sub-micron size range of the CBZ particles, as described by the Scherrer equation, 
influences the broadness of the PXRD peaks observed throughout this study.
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Figure 4. Powder X-ray diffraction patterns of theoretical CBZ polymorphic forms (I, II, and 
III) from the Cambridge Structural Database (CSD)64-66 and CBZ samples processed without 
additives in a SASD process at various solution flow rates. 
Figure 4 shows that the metastable form I, with small impurities from the stable form III, of 
CBZ was produced at each flow rate without the use of additives. This result would serve as a 
control to investigate if certain additives have an effect on the polymorphism of CBZ using the 
SASD process. 
A preliminary SASD screening with the additives reported in Table 3 appeared to uphold the 
reported results by Padrela et al. for certain additives in their batch supercritical process.26 Each 
experiment presented in Table 3 and Fig. 5 was repeated at least three times. 
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Figure 5. Powder X-ray diffraction patterns of theoretical CBZ polymorphic forms (I, II, and 
III) from the Cambridge Structural Database (CSD)64-66 and CBZ samples processed with 
additives produced by the SASD method (SASD 4-11), reported in Table 3. 
The results obtained from the screening runs presented in Fig. 5 show that (1) amorphous CBZ 
was obtained when using Ethyl Cellulose (SASD 7) as additives, (2) PXRD-pure CBZ form I 
was obtained when using either Maltitol (run SASD 5) or L-Eudragit 100-55 (run SASD 9) as 
additives, (3) PXRD-pure CBZ form II was obtained when using sodium stearate (run SASD 
6) as additive, and (4) PXRD-pure CBZ form III was obtained when using sodium dodecyl 
sulfate (run SASD 8) as an additive. The anionic additives sodium stearate (which promotes 
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the form of CBZ form II) and sodium dodecyl sulfate (which promotes the formation of CBZ 
form III) were selected for further investigation. A Design of Experiments (DoE) approach was 
applied for each additive to determine if the results obtained would be as robust across a range 
of distinct processing conditions. The processing parameters selected for this DoE study were; 
i) the % of additive (w/w) used and ii) the solution flow rate. Additive quantity was selected as 
a parameter to investigate if a minimum and maximum threshold could be determined where 
the additive would have an effect on the final polymorphic form obtained. Solution flow rate 
was selected as a parameter due to its ability to vary the solution to supercritical CO2 antisolvent 
mass flow ratio, as observed in Table 2. This ratio is expected to affect the supersaturation of 
the CBZ solution in the SASD nozzle, which may influence the polymorph obtained. This ratio 
may also provide an insight into the crystallization mechanism involved in our SASD 
experiments which will be discussed in this manuscript.
The primary crystallization mechanism is predicted to be antisolvent nucleation/crystallization, 
induced by high supersaturation levels inside the high-pressure SASD nozzle. This prediction 
stems from the results obtained in the precipitation of carbamazepine in a batch supercritical 
antisolvent process. As the pressure increases, the solvating power and the miscibility of CO2 
with methanol increase, causing CBZ to precipitate. An alternative mechanism for the 
production of these CBZ nanoparticles is the evaporation of solvent during the spray drying 
step in the drying chamber. This drying step is necessary in this process to remove the solvent 
(methanol) from the atomized suspension droplets and convert them into a fine dried powder. 
The removal of solvent must be efficient to prevent any polymorphic conversion of CBZ in the 
final samples. In attempts to replicate the antisolvent mechanism observed in the batch 
precipitation process, a solution to CO2 mass flow ratio of 0.011 was used, which falls below 
the maximum allowed ratio of 0.5 for antisolvent crystallization to occur at a working 
temperature of 50 °C (see Table 6). At the end of these experiments, upon disassembling the 
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apparatus, a small portion of fine powder was observed inside the mixing chamber of the SASD 
nozzle, indicating that antisolvent nucleation/crystallization of CBZ occurred in the screening 
experiments. 
Figure 6 presents a Design of Experiments (DoE) to investigate the effect of additive (sodium 
dodecyl sulfate) quantity and solution flow rate on the polymorphic forms of CBZ obtained by 
SASD. 
Figure 6. a) Design of Experiments (DoE) schematic to investigate the effect of additive 
(sodium dodecyl sulfate) quantity and solution flow rate on the polymorphic forms of CBZ 
obtained by supercritical antisolvent assisted nano spray drying (SASD). b) Powder X-ray 
diffraction patterns of theoretical CBZ polymorphic forms (I, II, III and IV) from the 
Cambridge Structural Database (CSD)64-67 and CBZ samples processed through SASD with 
SDS as the additive. Asterisks (*) represent unidentified peaks (9° 2 Theta) that cannot be 
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attributed to any CBZ polymorph or additive. Experimental conditions as described in Table 
4.
Figure 6 shows that the process parameters studied in this DoE (e.g. solution flow rate, % of 
additive) do not seem to significantly influence the polymorphic outcome of carbamazepine. 
In a batch supercritical antisolvent process, SDS favors the formation of pure form III of CBZ. 
26Similarly, in a continuous antisolvent-assisted nano spray drying process, form III of CBZ is 
consistently obtained for the different ratios of additive (SDS) and solution flow rates used 
(Fig. 6). However, Fig. 6 shows the presence of small amounts of impurity peaks at ca. 12° (2 
Theta) corresponding to CBZ form I at DoE Points 1, 2 ,3 and 5. This impurity corresponds to 
the dominant form obtained when additives were not used. Interestingly, an unknown peak at 
ca. 9° (2 Theta) appears in the powder X-ray diffractograms of the samples produced in the 
DoE points 1 to 5 (Fig. 6). This peak requires further investigation to explore the reason for its 
appearance when using SDS. This result (obtaining the stable form III) is of particular interest 
as the time between nucleation and precipitation in the SASD nozzle is in the range of 
milliseconds, and as a result, it is typically difficult to obtain a stable polymorph. This is due 
to the fact that according to Ostwald’s rule, it is not the most stable but the least stable 
polymorph that crystallizes first. Indeed, supercritical CO2 methods typically favor the 
formation of metastable crystalline forms most likely due to the peculiar/unique antisolvent 
effect of CO2. Comparatively, conventional spray drying is a flash process (without using CO2) 
that is typically used to produce amorphous samples, which represent the least 
thermodynamically stable forms of an API. 
Table 4 also shows the experimental conditions used for this DoE using SS, including the ratio 
of solution to SCF which will be discussed in further detail later in this section. Figure 7 
presents a schematic of the DoE studied when SS was used as the additive in the SASD 
experiments.
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Figure 7. a) Design of Experiments (DoE) schematic to investigate the effect of additive 
(sodium stearate) quantity and solution flow rate on the polymorphic forms of CBZ obtained 
by supercritical antisolvent assisted nano spray drying (SASD). b) Powder X-ray diffraction 
patterns of theoretical CBZ polymorphic forms (I, II, III and IV) from the Cambridge Structural 
Database (CSD)64-67 and CBZ samples processed through SASD with sodium stearate as the 
additive. Experimental conditions as described in Table 4.
Figure 7 shows that the % of SS influences the polymorphism of CBZ nanoparticles produced 
by supercritical antisolvent assisted nano spray drying (SASD). All samples processed with SS 
resulted in the generation of CBZ form II as the dominant polymorph observed. At low 
quantities (1%), the presence of small peaks corresponding to CBZ form I are observed while 
at higher quantities (10%), the form I impurities begin to decrease but are not completely 
removed. At the mid-point (DoE Point 10), pure form II was observed which may represent 
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the optimum quantity of additive required to control the polymorphic form of CBZ. The results 
from Fig. 7 indicate that the results previously obtained by Padrela et al., demonstrating that 
SS results in the templating of CBZ molecules to generate form II, is upheld when selecting 
the SASD technique. Although most samples generated are not PXRD pure, the presence of 
minor impurities (of CBZ form I) from other polymorphic forms are likely the cause of the 
technique used. When additives are not used, there is a tendency to generate CBZ form I (seen 
in Fig. 4) and this may be the cause of these minor impurities observed in Fig. 7. Both 
parameters (quantity of additive and solution flow rate) do not appear to influence the 
polymorphic form generated in all samples when selecting this additive.
SASD versus conventional spray drying
An important aspect that distinguishes the SASD process from conventional spray drying 
(which typically uses N2 to dry a solution) concerns the unique precipitation mechanism 
induced by the antisolvent effect of supercritical CO2 in the coaxial nozzle. The 
supersaturation/antisolvent mechanism induced by supercritical CO2 provides a unique feature 
to spray drying processes to control drug polymorphism. In a Buchi conventional spray dryer, 
there is no antisolvent crystallization occurring in the nozzle, with solvent evaporation being 
the governing precipitation mechanism happening during the spray drying step. The low 
miscibility of the N2 as well as the poor anti-solvent power provides a good assessment of the 
anti-solvent performance of CO2.68 Therefore, any differences between the polymorphic forms 
of CBZ obtained from conventional spray drying and the SASD process would strongly suggest 
that the mechanism that governs crystallization and polymorphic control in SASD is caused by 
the antisolvent effect of CO2. 
Table 5 shows the experimental conditions used in the conventional spray drying (SD) where 
the additives sodium stearate and sodium dodecyl sulfate were used. Figure 8 presents powder 
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X-ray diffraction patterns for CBZ samples (with/without additives) processed by SASD and 
conventional spray drying methods.
Figure 8.  Powder X-ray diffraction patterns of theoretical CBZ polymorphic forms (I, II, III 
and IV) from the Cambridge Structural Database (CSD)64-67 and CBZ samples (with/without 
additives) processed by supercritical antisolvent assisted nano spray drying (SASD) and 
conventional spray drying (SD) methods. When additives were selected, the quantity was 5% 
w/w (2.5 mg/ml).
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Using processing conditions in conventional spray drying (SD) as similar as possible to the 
supercritical antisolvent assisted nano spray drying (SASD) processing conditions (outlet 
temperature of 50°C; 50 mg/ml of CBZ in methanol), it was observed that the metastable form 
IV of CBZ was obtained by SD which differed from the polymorph produced using the SASD 
technique (CBZ form I). The result obtained from conventional spray drying corresponds well 
with the results obtained by Halliwell et al. that concluded that this technique is a robust method 
for the production of form IV of CBZ.23 Interestingly, when either sodium stearate (SS) or 
sodium dodecyl sulfate (SDS) were used in the conventional spray drying (SD) experiments, 
form IV was also obtained. However, form II (when using SS as the additive) and form III 
(when using SDS as the additive) were the primary forms obtained in SASD. These results 
suggest that anionic molecular additives influence the polymorphism of CBZ specifically when 
supersaturation is generated by the CO2 antisolvent effect. 
The SEM analysis in Fig. 9 confirms the expected shape for each crystal form produced. 
Carbamazepine nanoparticles processed with SS by the SASD method display a long needle-
shape (Fig. 9c) which is characteristic of form II. Block-shaped particles (Fig. 9d) were 
observed for CBZ samples processed with SDS, which corresponded to the form III. Needle-
shape particles (Fig. 9b) in the form of aggregates belonging to form I were produced without 
the use of additives. 
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Figure 9. Scanning electron microscopy (SEM) images of raw CBZ and CBZ samples 
produced from different SASD runs: a) raw CBZ as form III; b) CBZ form I produced without 
additives (SASD 4); c) CBZ form II produced with sodium stearate (SASD 6); d) CBZ form 
III produced with sodium dodecyl sulfate (SASD 8).
Particle size analysis varied depending on the polymorphic form obtained. Due to the needle-
like shape of CBZ forms I and II, the width was determined which resulted in a much lower 
mean particle size than form III particles (block-shaped). SASD processed Form I samples 
showed a mean particle size of 120 ± 37 nm while form II particles showed an average size of 
94±39nm. Form III particles showed a mean size of 1 ± 0.42 µm, primarily due to the difference 
in shape. The Gaussian distribution of each sample is provided in the Supporting Information 
(Figs. SI1, SI2, SI3 and SI4). The particle size of the raw CBZ samples (form III) was also 
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analyzed, which was determined to be 59±13µm. This highlights the potential of the SASD 
method for the production of nano-sized particles of pharmaceutical drugs.
A final confirmation that antisolvent supersaturation/nucleation is likely to occur in the nozzle 
during the SASD experiments relates to the mass flow-rate ratio of solution and supercritical 
CO2 when compared to the mass ratio obtained in a batch supercritical antisolvent process. For 
the precipitation tests presented in Table 6, the mechanism that caused precipitation of CBZ 
was CO2 antisolvent crystallization. The ratio of solution to supercritical CO2 should allow us 
to determine the minimum value needed for antisolvent crystallization to occur. Calculating 
the mass ratios of solution to supercritical CO2 in the batch supercritical process was 
completed, as described in the Experimental Section. In the batch supercritical antisolvent 
process, there was a mass ratio of solution to supercritical CO2 of 0.49-0.55 (depending on the 
temperature used) required to achieve for the precipitation of CBZ from methanol solutions. 
At the median solution flow rate (0.25 ml/min) and at 50 °C, the flow-rate ratio of solution to 
supercritical CO2 used was 0.013 (SASD 2 in Table 2), which shows that there is a significantly 
higher proportion of CO2 than solution inside the nozzle. As this value is significantly less than 
0.50 (the maximum mass ratio allowed for antisolvent crystallization of CBZ to occur in a 
batch reactor at 50 °C), there is a strong indication that supersaturation of the CBZ solutions 
occurs in the SASD nozzle, caused by the CO2 antisolvent effect. This supersaturation of the 
CBZ solutions induced by the CO2 antisolvent effect, associated with the presence of each 
additive, promotes the nucleation of a particular polymorph of CBZ in the nozzle, followed by 
its crystallization in the drying chamber.
In order to test this hypothesis, the concentration of CBZ in methanol was reduced to 1/3 of the 
initial value (17.0 mg/ml) and processed using the SASD technique (see Table 3). Figure 10 
shows the PXRD diffractograms of CBZ samples produced from low concentration CBZ 
methanol solutions (C[CBZ] = 17.0 mg/ml) by the SD and SASD methods. 
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Figure 10. Powder X-ray diffraction patterns of theoretical CBZ polymorphic forms (I, II, III 
and IV) from the Cambridge Structural Database (CSD)64-67 and CBZ samples processed 
using SASD and conventional spray drying (SD) methods. A low concentration of CBZ in 
the methanol solutions was used (17.0 mg/ml), as described in Tables 3 and 5. When 
additives were selected, the quantity used was 5% w/w (0.8 mg/ml).
The SASD experiments yielded amorphous CBZ samples, regardless of whether an additive 
was used. This shows that as we decrease the concentration of CBZ in the methanol solutions, 
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the levels of supersaturation achieved inside the SASD nozzle are significantly reduced which 
does not promote nucleation and crystallization of CBZ. By reducing the concentration of the 
CBZ solutions (to 17.0 mg/ml of CBZ in methanol), supersaturation of CBZ in the SASD 
nozzle is unlikely to occur, which leads to the amorphization of CBZ during the spray drying 
step (after the nozzle exit). Using identical concentrations of CBZ in methanol and similar 
operating conditions in a conventional spray dryer resulted in CBZ form IV. As there is no 
antisolvent supersaturation occurring in the conventional spray drying (SD) process (rather 
solvent evaporation being the main precipitation mechanism in this method), this result further 
supports our hypothesis that antisolvent supersaturation is the governing precipitation 
mechanism in the supercritical CO2 antisolvent-assisted nano spray drying (SASD) method. 
The stability of CBZ samples produced by the SASD process is presented and discussed in 
detail in the Supplementary Information.
Conclusions
This work demonstrates that the polymorphic outcome of carbamazepine (CBZ) is controllable, 
with only minor polymorphic impurities, using anionic additives in a continuous supercritical 
CO2 assisted nano spray drying process (SASD). Both SEM and PXRD results show that using 
sodium stearate promotes the formation of CBZ form II across a range of processing conditions 
(e.g. solution flow-rate and % of additive used) in the SASD process, while sodium dodecyl 
sulfate promotes the formation of the stable CBZ form III. The results presented herein suggest 
that the primary mechanism that governs the crystallization of CBZ in the SASD process is the 
occurrence of supersaturation in the nozzle caused by the antisolvent effect of supercritical 
CO2. We suggest that the anionic additives used in this work template form II (when using 
sodium stearate as an additive) or form III (when using sodium dodecyl sulfate as an additive) 
of CBZ during the nucleation stage in the SASD nozzle. This leads to the crystallization of 
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each particular polymorph during the spray-drying step (after the nozzle exit). Additionally, 
the ratio of solution to supercritical CO2 is considerably high in the SASD process when 
compared to the values obtained in the batch supercritical antisolvent experiments, strongly 
indicating that antisolvent nucleation should be occurring in the nozzle. 
These results could not be replicated when using similar processing conditions in conventional 
spray drying (where antisolvent supersaturation does not occur).  The difference in mechanisms 
between these the SASD and the SD methods is clearly observed by the different polymorphic 
outcomes of CBZ obtained. Depending on the additive used, the SASD process produces forms 
I, II or III, while conventional spray drying consistently produces form IV only, irrespective of 
the additive selected. In addition to this, when the concentration of the CBZ solution is reduced, 
supersaturation in the SASD nozzle is unlikely to be achieved and, as a result, antisolvent 
nucleation/crystallization would not occur in the SASD process (amorphous CBZ samples are 
produced) while the metastable form IV of CBZ is consistently produced when using 
conventional spray drying (SD). 
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List of Figures
Figure 1.  Schematic diagram of the batch supercritical antisolvent apparatus used for 
solubility testing. 1, CO2 cylinder; 2, gas compressor; 3, temperature controlled air chamber; 
4, stainless steel storage cylinder; 5, magnetic stirrer plate; 6, high-pressure vessel; 7, exit 
valve; Pc: pressure controller; Tc: temperature controller.
Figure 2. Schematic diagram of the continuous SASD apparatus. 1, CO2 cylinder; 2, gas 
compressor; 3, CBZ solution flask connected to a HPLC pump; 4, temperature-controlled CO2 
storage cylinder; 5, high-pressure nozzle; 6, drying chamber; 7, filter; 8, Temperature 
controlled air chamber; Tc: temperature controller; Pc: pressure controller;.
Figure 3. Design of Experiment (DoE) schematic to investigate the effect of additive quantity 
and solution flow rate on the polymorphic forms of CBZ obtained by the SASD process.
Figure 4. Powder X-ray diffraction patterns of theoretical CBZ polymorphic forms (I, II, and 
III) from the Cambridge Structural Database (CSD)64-66 and CBZ samples processed without 
additives in a SASD process at various solution flow rates. 
Figure 5. Powder X-ray diffraction patterns of theoretical CBZ polymorphic forms (I, II, and 
III) from the Cambridge Structural Database (CSD)64-66 and CBZ samples processed with 
additives produced by the SASD method (SASD 4-11), reported in Table 3. 
Figure 6. a) Design of Experiments (DoE) schematic to investigate the effect of additive 
(sodium dodecyl sulfate) quantity and solution flow rate on the polymorphic forms of CBZ 
obtained by supercritical antisolvent assisted nano spray drying (SASD). b) Powder X-ray 
diffraction patterns of theoretical CBZ polymorphic forms (I, II, III and IV) from the 
Cambridge Structural Database (CSD)64-67 and CBZ samples processed through SASD with 
SDS as the additive. Asterisks (*) represent unidentified peaks (9° 2 Theta) that cannot be 
attributed to any CBZ polymorph or additive. Experimental conditions as described in Table 
4.
Page 37 of 41
ACS Paragon Plus Environment






























































Figure 7. a) Design of Experiments (DoE) schematic to investigate the effect of additive 
(sodium stearate) quantity and solution flow rate on the polymorphic forms of CBZ obtained 
by supercritical antisolvent assisted nano spray drying (SASD). b) Powder X-ray diffraction 
patterns of theoretical CBZ polymorphic forms (I, II, III and IV) from the Cambridge Structural 
Database (CSD)64-67 and CBZ samples processed through SASD with sodium stearate as the 
additive. Experimental conditions as described in Table 4.
Figure 8.  Powder X-ray diffraction patterns of theoretical CBZ polymorphic forms (I, II, III 
and IV) from the Cambridge Structural Database (CSD)64-67 and CBZ samples (with/without 
additives) processed by supercritical antisolvent assisted nano spray drying (SASD) and 
conventional spray drying (SD) methods. SS – sodium stearate; SDS – sodium dodecyl sulfate.
Figure 9. Scanning electron microscopy (SEM) images of raw CBZ and CBZ samples 
produced from different SASD runs: a) raw CBZ as form III; b) CBZ form I produced without 
additives (SASD4); c) CBZ form II produced with sodium stearate (SASD 6); d) CBZ form III 
produced with sodium dodecyl sulfate (SASD 8).
Figure 10. Powder X-ray diffraction patterns of theoretical CBZ polymorphic forms (I, II, III 
and IV) from the Cambridge Structural Database (CSD)64-67 and CBZ samples processed 
using SASD and conventional spray drying (SD) methods. A low concentration of CBZ in 
the methanol solutions was used (17.0 mg/ml), as described in Tables 3 and 5. SS: sodium 
stearate; SDS: sodium dodecyl sulfate.
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Table 1. Type of Additives Used in the Preparation of Carbamazepine Solutions in Methanol 
for Supercritical-CO2 Antisolvent-Assisted Nano Spray Drying
Table 2. List of Carbamazepine (CBZ) Solid Forms Obtained at Different Solution Flow Rates 
Without the Use of Additives Using Supercritical CO2 Antisolvent-Assisted Nano Spray 
Drying (SASD) a
Table 3. List of Carbamazepine (CBZ) Solid Forms Obtained Using Supercritical CO2 
Antisolvent-Assisted Nano Spray Drying (SASD) b
Table 4. Experimental Conditions Used in SASD Runs for a Design of Experiments (DoE) 
using Sodium Dodecyl Sulfate (SDS) and Sodium Stearate (SS) as Additives c  
Table 5. Experimental Conditions used in Conventional Spray Drying (SD) Runs and List of 
Carbamazepine (CBZ) Solid Forms Obtainedd 
Table 6. Experimental Conditions Required for the Precipitation of Carbamazepine in a Batch 
Supercritical Antisolvent Process e 
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This work demonstrates a novel methodology to control the polymorphism of carbamazepine 
nanoparticles using a novel continuous supercritical CO2 assisted nano spray drying (SASD) 
process. The type of additive used influenced the final polymorphic form of carbamazepine 
produced by SASD (when antisolvent supersaturation occurs in the nozzle) but not by 
conventional spray drying. 
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